NasdaqGS:BBIOBiotechs
BridgeBio Priority Review Puts BBP-418 And Valuation In Investor Focus
FDA has granted Priority Review for BridgeBio Pharma's BBP-418 for limb-girdle muscular dystrophy type 2I/R9.
If approved, BBP-418 could become the first and only therapy for LGMD2I/R9 and the first treatment for any form of LGMD.
The Priority Review follows acceptance of BridgeBio's NDA and is tied to plans for a near-term commercial launch.
For investors following BridgeBio Pharma (NasdaqGS:BBIO), this regulatory step sits alongside a share price of $66.26, a 3-year return of around 4x,...